Standout Papers

EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previou... 2023 2026 202470
  1. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma (2023)
    Jonathan E. Rosenberg, Thomas Powles et al. Annals of Oncology

Immediate Impact

1 by Nobel laureates 65 standout
Sub-graph 1 of 22

Citing Papers

Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
2025 Standout
Advances in diagnosis and treatment of bladder cancer
2024 Standout

Works of J.-L. Lee being referenced

EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
2023 Standout

Author Peers

Author Last Decade Papers Cites
J.-L. Lee 209 132 126 11 318
Mohamad Khasawneh 221 93 180 8 328
S. Négrier 322 88 258 9 368
S. T. Kim 291 114 248 16 366
Tomohiro Funakoshi 109 109 94 11 320
Marianne Taylor 113 172 151 12 332
Christopher Hocking 178 170 103 15 320
Yingsi Yang 83 158 82 13 293
Ki Sun Jung 149 145 196 21 337
Seon-Hee Yim 57 129 73 11 297
Riaz Alvi 93 254 83 15 360

All Works

Loading papers...

Rankless by CCL
2026